GlassScriptPhysician profile
Vanessa Marion
NPI 1790487411
$2,149.90
in general payments reported to CMS, 2019-2025
30 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $511 · 2024: $1,532 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.90 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $250.40 | 2023-2024 | Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $242.80 | 2024 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $195.95 | 2023-2024 | Tecvayli, Erleada, Balversa |
| Lilly USA, LLC | $139.26 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $118.09 | 2023-2024 | Enhertu |
| Astellas Pharma US INC | $99.00 | 2024 | |
| Eisai INC. | $98.85 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $87.02 | 2024-2025 | Enhertu |
| Taiho Oncology, INC. | $78.51 | 2024 | |
| Coherus Oncology, INC. | $74.62 | 2024-2025 | Loqtorzi, Udenyca |
| Mirati Therapeutics, INC. | $71.34 | 2023-2024 | Krazati |
| Gilead Sciences, INC. | $64.29 | 2024 | |
| Stemline Therapeutics INC. | $64.04 | 2023-2024 | Orserdu |
| Puma Biotechnology, INC. | $62.76 | 2023-2024 | |
| Seagen INC. | $59.22 | 2023 | Tukysa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $53.93 | 2024 | Tivdak, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $53.69 | 2024 | Ninlaro, Vpriv |
| Pfizer INC. | $53.37 | 2024 | |
| Novartis Pharmaceuticals Corporation | $44.79 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $32.17 | 2024 | Provenge |
| Karyopharm Therapeutics INC. | $30.40 | 2024 | Xpovio |
| Janssen Pharmaceuticals, INC | $29.39 | 2023 | Xarelto |
| Genzyme Corporation | $25.15 | 2024 | |
| Sumitomo Pharma America, INC. | $21.63 | 2024 | Orgovyx |
| G1 Therapeutics, INC. | $19.50 | 2023 | Cosela |
| Tersera Therapeutics LLC | $18.71 | 2024 | Zoladex |
| Pharmaessentia USA Corporation | $17.41 | 2024 | Besremi |
| Glaxosmithkline, LLC. | $16.24 | 2025 | Jemperli |
| Deciphera Pharmaceuticals INC. | $14.12 | 2023 | Qinlock |
| Tactile Systems Technology INC | $13.25 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Marion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.